UPV spin off receives one million euros for the development of ACORYS, a medical device designed to improve the effectiveness and treatment of Atrial Fibrillation.

Corify Care, a spin off company of the Polytechnic University of Valencia (UPV), has obtained a one million euros grant from the Research and Development Centre for Industrial Technology Development (CDTI) of the Spanish Ministry of Science and Innovation.

This grant will be destinated for the development of ACORYS, a medical device that, using technology created by the Hospital General Universitario Gregorio Marañón and the UPV, enhances the effectiveness and non-invasive treatment of atrial fibrillation, a cardiac arrhythmia that affects more than 10 million people just across Europe.

Related posts
Corify Care Launches First U.S. Clinical Trial (AI4AF) at Mayo Clinic

MADRID, Spain – June, 2026  Corify Care expands its clinical footprint to the United States with the initiation of the ACORYS-AI4AF trial...

Read More »
Corify Care Validates 4-D Global Cardiac Mapping for Complex Atrial and Ventricular Arrhythmias 

New publications in Heart Rhythm and Europace demonstrate how single-beat mapping provides instant clinical clarity, optimizing ablation strategies and improving patient...

Read More »
Corify Care Receives FDA Clearance for ACORYS® — Introducing Instant, 4-D Electroanatomical Cardiac Mapping in Real-time 

MADRID, Spain – April, 2026 – Corify Care today announced that the U.S. Food and Drug Administration (FDA) has granted clearance for...

Read More »